EMA Authorised: Zavesca (miglustat) — Janssen Cilag International NV

View source ↗

Summary

EMA authorised Zavesca (miglustat) for Gaucher disease and Niemann-Pick diseases; Janssen Cilag International NV is the marketing authorisation holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gaucher Disease
• Niemann-pick Disease

Drugs mentioned

• Zavesca (Miglustat)

Snippet

Status: Authorised. Therapeutic area: Gaucher Disease;Niemann-Pick Diseases. MAH: Janssen Cilag International NV. Decision date: 25/10/2024